2024年7月12日，trinity biotech與Craig-Hallum資本集團簽訂ATM發行協議，根據協議，trinity biotech可以賣出價值550萬美元的ADS股票，每個ADS股票代表公司20個A類普通股（trinity biotech還將支付Craig-Hallum一筆代理費）。
該協議可能通過多項或單項交易在納斯達克上進行，或者其他任何可交易的場所或市場銷售。此次發行的ADS股票將發行給投資者，價格將根據市場價格而定。
On July 12, 2024, Trinity Biotech Entered Into An ATM Offering Agreement With Craig-Hallum Capital Group, Pursuant To Which May Sell Up To $5.5M Of Its ADSs, Each ADS Representing 20 Of The Company's A Ordinary Shares (Co Will Also Pay Craig-Hallum A...
On July 12, 2024, Trinity Biotech Entered Into An ATM Offering Agreement With Craig-Hallum Capital Group, Pursuant To Which May Sell Up To $5.5M Of Its ADSs, Each ADS Representing 20 Of The Company's A Ordinary Shares (Co Will Also Pay Craig-Hallum A...
On July 12, 2024, Trinity Biotech Entered Into An ATM Offering Agreement With Craig-Hallum Capital Group, Pursuant To Which May Sell Up To $5.5M Of Its ADSs, Each ADS Representing 20 Of The Company's A Ordinary Shares (Co Will Also Pay Craig-Hallum A Commission Equal To 3% Of The Gross Sales Price Of ADSs)
2024年7月12日，Trinity Biotech與Craig-Hallum Capital Group簽訂ATM Offering協議，根據此協議可能出售多達550萬美元的ADS，每個ADS代表公司20股A類普通股（公司還將向Craig-Hallum支付其ADS毛售價3%的佣金）。
On July 12, 2024, Trinity Biotech plc (the "Company") entered into an At the Market Offering Agreement (the "Sales Agreement") with Craig-Hallum Capital Group LLC ("Craig-Hallum"), pursuant to which the Company may sell up to $5,500,000 of its American Depositary Shares ("ADSs"), each ADS representing 20 of the Company's A Ordinary Shares, par value $0.0109 per share, from time to time, through Craig-Hallum, acting as sales agent.
2024年7月12日，Trinity Biotech plc（以下簡稱“公司”）與Craig-Hallum Capital Group LLC（以下簡稱“Craig-Hallum”）簽訂了“At the Market Offering Agreement（下稱“Sales Agreement”）協議，根據此協議公司可能通過銷售代理商Craig-Hallum，不時銷售高達5,500,000美元的美國存托股票（以下簡稱“ADSs”），每個ADS代表公司20股普通A類股，每股面值0.0109美元。
Subject to the terms and conditions of the Sales Agreement, the Company will, from time to time, set the parameters for the sale of ADSs, including any price, time or size limits or other customary parameters or conditions, and Craig-Hallum will use its commercially reasonable efforts to sell the ADSs when requested by the Company. The Sales Agreement is filed herewith as Exhibit 1.1.
根據Sales Agreement的條款和條件，公司將不時確定ADS的銷售參數，包括任何價格，時間或大小限制，或其他慣常參數或條件，Craig-Hallum會在公司要求時盡其商業合理努力出售ADS。Sales Agreement作爲附件1.1提交。
In the Sales Agreement, the Company has agreed to provide Craig-Hallum with customary indemnification rights. The Company will also pay Craig-Hallum a commission equal to 3.0% of the gross sales price of ADSs sold pursuant to the Sales Agreement.
在Sales Agreement中，公司同意向Craig-Hallum提供慣常的賠償權利。此外，公司還將向Craig-Hallum支付合同約定ADS毛售價3.0%的佣金。
Sales of the ADSs under the Sales Agreement may be made by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.
在Sales Agreement項下，ADS的銷售可以採用任何法律允許的方法，被認爲是1933年證券法修正案第415(a)(4)條規定的“現場發售”（at the market offering）。